Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7?36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships

GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MAN

1987 • 1,845 citations

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients

1993 • 1,064 citations

Truncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man

1993 • 661 citations

Biological Effects and Metabolic Rates of Glucagonlike Peptide-1 7–36 Amide and Glucagonlike Peptide-1 7–37 in Healthy Subjects Are Indistinguishable

1993 • 311 citations

Gut hormones and diabetes mellitus

1992 • 182 citations

Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans

1994 • 126 citations

Radio-immunoassays for glucagon-like peptides 1 and 2 (GLP-1 and GLP-2)

1987 • 117 citations

Human glucagon‐like peptides 1 and 2 activate rat brain adenylate cyclase

1984 • 111 citations

Identification and characterization of glucagon‐like peptide‐1 7–36 amide‐binding sites in the rat brain and lung

1988 • 110 citations

Glucagonlike peptide I (7-37) actions on endocrine pancreas

1989 • 69 citations

Evidence that peak II GLI or enteroglucagon is identical to the C-terminal sequence (residues 33–69) of glicentin

1983 • 27 citations